Game-changing pan-TEAD inhibitor for solid tumours
Drug Target Review
JUNE 12, 2023
With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. The system optimised the molecules that were most likely to succeed in terms of potency, metabolic stability, synthetic accessibility, and more.
92 
Let's personalize your content